Tag: Immunotherapy
MSI-H Colorectal Cancer Rarely Recurs After Immunotherapy Cessation
88 percent of 64 patients remained without disease progression after median of 22.6 months after stopping immunotherapy
ASH: Ibrutinib-Venetoclax Beneficial for Relapsed/Refractory Lymphoma
Improvement seen in progression-free survival for patients with relapsed/refractory mantle cell lymphoma
ASH: Daratumumab Beneficial for Patients With Multiple Myeloma
Addition of daratumumab to VRd results in improved progression-free survival for transplantation-eligible patients
Study Looks at Survival in Metastatic NSCLC Treated With Immunotherapy
Survival similar among racial and ethnic groups; ECOG performance status linked to survival
ASH: MRD-Directed Ibrutinib-Venetoclax Treatment Beneficial in Leukemia
Improvement in survival seen with measurable residual disease-directed ibrutinib-venetoclax versus fludarabine-cyclophosphamide-rituximab
ASH: Axi-Cel CAR T-Cell Treatment Effective in High-Risk Lymphoma Patients
Five-year PFS was 28.5 percent and overall survival was 40.3 percent; 40.2 percent of patients did not meet ZUMA-1 eligibility criteria
Adverse Events Up With Immune Checkpoint Blockade Added to Periop Cancer Therapy
Increase seen in incidence of grade 3 to 4 treatment-related adverse events, adverse events leading to treatment discontinuation
Sublingual Immunotherapy Safe, Effective for Treating Toddlers’ Peanut Allergy
Improved outcomes seen with younger age at initiation
Atezolizumab Can Induce Response in Alveolar Soft Part Sarcoma
Anti-PD-L1 agent induces sustained responses seen in about one-third of patients with advanced alveolar soft part sarcoma
Zolbetuximab Plus CAPOX Beneficial for Advanced mG/GEJ Adenocarcinoma
Progression-free survival and overall survival prolonged with zolbetuximab plus CAPOX versus placebo plus CAPOX
